Another Tool in the Toolbox: Updates on Improving Renal and Cardiovascular Outcomes in CKD in T2D

CE / CME

Another Tool in the Toolbox: Updates on Improving Renal and Cardiovascular Outcomes in CKD in T2D
Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: May 23, 2022

Expiration: May 22, 2023

George L. Bakris
George L. Bakris, MD
Lucia M Novak
Lucia M Novak, MSN, ANP-BC, BC-ADM

Pretest

Progress
1 2
Course Completed
1.
Which of the following statements is true regarding the relationship of chronic kidney disease (CKD) and diabetes to cardiovascular (CV) risk?
2.
When screening patients with T2D for CKD, how often should estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) be measured at minimum?
3.
Which of the following patient factors would most likely indicate benefit from the initiation of finerenone?
4.
How often do you currently discuss lifestyle modifications to reduce CV risk with your patients with CKD and T2D?
5.
How often do you currently ensure your patients with T2D without a current CKD diagnosis have annual eGFR and UACR testing?
6.
How often do you consider the use of a nonsteroidal mineralocorticoid receptor antagonist for your patients with CKD, T2D, and risk for CV events?